Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma.

Chen L, Wang S, Zhou Y, Wu X, Entin I, Epstein J, Yaccoby S, Xiong W, Barlogie B, Shaughnessy JD Jr, Zhan F.

Blood. 2010 Jan 7;115(1):61-70. doi: 10.1182/blood-2009-03-210526. Epub 2009 Oct 16.

2.

The effects of bortezomib on bone disease in patients with multiple myeloma.

Mohty M, Malard F, Mohty B, Savani B, Moreau P, Terpos E.

Cancer. 2014 Mar 1;120(5):618-23. doi: 10.1002/cncr.28481. Epub 2013 Nov 18. Review.

3.

Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects.

Reagan MR, Ghobrial IM.

Clin Cancer Res. 2012 Jan 15;18(2):342-9. doi: 10.1158/1078-0432.CCR-11-2212. Epub 2011 Nov 7. Review.

4.

Macrophages in multiple myeloma: emerging concepts and therapeutic implications.

Asimakopoulos F, Kim J, Denu RA, Hope C, Jensen JL, Ollar SJ, Hebron E, Flanagan C, Callander N, Hematti P.

Leuk Lymphoma. 2013 Oct;54(10):2112-21. doi: 10.3109/10428194.2013.778409. Epub 2013 Apr 11. Review.

5.

Evolutionary biology of high-risk multiple myeloma.

Pawlyn C, Morgan GJ.

Nat Rev Cancer. 2017 Aug 24;17(9):543-556. doi: 10.1038/nrc.2017.63. Review.

PMID:
28835722
6.

Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways.

Manni S, Carrino M, Piazza F.

J Hematol Oncol. 2017 Oct 2;10(1):157. doi: 10.1186/s13045-017-0529-5. Review.

Supplemental Content

Support Center